Talecris recognizes that long-term viability of a strong biopharmaceutical company depends on a solid product pipeline. A few of our ongoing projects are listed in the table below.
| Therapeutic Areas |
Product Type |
Uses |
Development Phase |
| Immunology and Neurology |
Immune globulin - subcutaneous |
Primary immune deficiency |
Phase III |
|
Immune globulin - intravenous |
Neurology/CIDP |
Completed. Approved Q3'08 in US and Canada. Pending approval in EU. |
| Thrombolytic |
Plasmin - plasma-derived |
Peripheral arterial occlusion |
Phase I |
|
Plasmin - recombinant |
Vascular occlusion |
Preclinical |
| Respiratory |
Alpha-1 protease inhibitor - modified process |
AAT deficiency |
Phase III |
|
Alpha-1 protease inhibitor - aerosol delivery |
AAT deficiency |
Preclinical |
Information about new and ongoing Talecris-sponsored clinical research studies can be found in the U.S. National Institute of Health registry at http://www.clinicaltrials.gov/.
Information related to Talecris-sponsored clinical research study results can be found at www.TalecrisClinicalStudies.com/.
|
